Role of Tissue Markers Associated with Tumor Microenvironment in the Progression and Immune Suppression of Oral Squamous Cell Carcinoma

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2023 Sep 21

PMID 37731058

Authors

Suganya Ramalingam

Sivaramakrishnan Shantha

Susruthan Muralitharan

Uma Sudhakar

Harikrishnan Thamizhchelvan

Venkatachalam Deepa Parvathi

Affiliations

Soon will be listed here.

Abstract

Head and neck cancers (HNC) continues to dominate major cancers contributing to mortality worldwide. Squamous cell carcinoma is the major type of HNC. Oral Squamous Cell Carcinoma grouped under HNC is a malignant tumor occurring in the oral cavity. The primary risk factors of OSCC are tobacco, alcohol consumption, etc. This review focuses on modulations, mechanisms, growth and differentiation of oral squamous cell carcinoma. Cancer cell surrounds itself with a group of elements forming a favorable environment known as tumor microenvironment (TME). It consists of numerous cells which includes immune cells, blood cells and acellular components that are responsible for the progression, immunosuppression, metastasis and angiogenesis of cancer. This review highlights the most important tissue biomarkers (mTOR, CAF, FOXp3, CD163, CD33, CD34) that are associated with TME cells. mTOR remains as the primary regulator responsible in cancer and its importance towards immune-suppression is highlighted. Tumor-associated macrophages associated with cancer development and its relationship with immunomodulatory mechanism and Tregs, which are potential blockers of immune response and its mechanism and aberrations are discussed. Cancer-associated fibroblasts that are a part of TME and their role in evading the immune response and myeloid derived suppressor cells that have slight control over the immune response and their mechanism in the tumor progression is further explained. These markers have been emphasised as therapeutic targets and are currently in different stages of clinical trials.

Citing Articles

Distant metastasis of oral squamous cell carcinoma: immune escape mechanism and new perspectives on treatment.

He L, Wan M, Yang X, Meng H Discov Oncol. 2025; 16(1):257.

PMID: 40024975 PMC: 11872995. DOI: 10.1007/s12672-025-01997-3.

Metabolic targeting of regulatory T cells in oral squamous cell carcinoma: new horizons in immunotherapy.

Gan M, Liu N, Li W, Chen M, Bai Z, Liu D Mol Cancer. 2024; 23(1):273.

PMID: 39696340 PMC: 11657557. DOI: 10.1186/s12943-024-02193-7.

Expression of mTOR, CD163, α-SMA, FOXp3 as survival predictors and its significance in patients with oral squamous cell carcinoma.

Ramalingam S, Shantha S, Srinivasan C, Priyathersini N, Muralitharan S, Sudhakar U BMC Oral Health. 2024; 24(1):1487.

PMID: 39695576 PMC: 11653707. DOI: 10.1186/s12903-024-05245-y.

CD34 as a potential prognostic indicator for camrelizumab response in advanced non-small-cell lung cancer: insights from digital spatial profiling.

Huang X, Tian B, Ren Z, Zhang J, Yan W, Mo Y Ther Adv Med Oncol. 2024; 16:17588359241289671.

PMID: 39429466 PMC: 11489950. DOI: 10.1177/17588359241289671.

Diagnostic Accuracy of [Ga]Ga Labeled Fibroblast-Activation Protein Inhibitors in Detecting Head and Neck Cancer Lesions Using Positron Emission Tomography: A Systematic Review and a Meta-Analysis.

Rizzo A, Miceli A, Racca M, Bauckneht M, Morbelli S, Albano D Pharmaceuticals (Basel). 2023; 16(12).

PMID: 38139791 PMC: 10748043. DOI: 10.3390/ph16121664.

References

Johnson D, Burtness B, Leemans C, Lui V, Bauman J, Grandis J . Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020; 6(1):92. PMC: 7944998. DOI: 10.1038/s41572-020-00224-3. View

Gormley M, Creaney G, Schache A, Ingarfield K, Conway D . Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors. Br Dent J. 2022; 233(9):780-786. PMC: 9652141. DOI: 10.1038/s41415-022-5166-x. View

Patterson R, Fischman V, Wasserman I, Siu J, Shrime M, Fagan J . Global Burden of Head and Neck Cancer: Economic Consequences, Health, and the Role of Surgery. Otolaryngol Head Neck Surg. 2020; 162(3):296-303. DOI: 10.1177/0194599819897265. View

Kennel T, Garrel R, Costes V, Boisselier P, Crampette L, Favier V . Head and neck carcinoma of unknown primary. Eur Ann Otorhinolaryngol Head Neck Dis. 2019; 136(3):185-192. DOI: 10.1016/j.anorl.2019.04.002. View

Mody M, Rocco J, Yom S, Haddad R, Saba N . Head and neck cancer. Lancet. 2021; 398(10318):2289-2299. DOI: 10.1016/S0140-6736(21)01550-6. View

Marur S, Forastiere A . Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment. Mayo Clin Proc. 2016; 91(3):386-96. DOI: 10.1016/j.mayocp.2015.12.017. View

Chamoli A, Gosavi A, Shirwadkar U, Wangdale K, Behera S, Kurrey N . Overview of oral cavity squamous cell carcinoma: Risk factors, mechanisms, and diagnostics. Oral Oncol. 2021; 121:105451. DOI: 10.1016/j.oraloncology.2021.105451. View

Spill F, Reynolds D, Kamm R, Zaman M . Impact of the physical microenvironment on tumor progression and metastasis. Curr Opin Biotechnol. 2016; 40:41-48. PMC: 4975620. DOI: 10.1016/j.copbio.2016.02.007. View

LeBleu V . Imaging the Tumor Microenvironment. Cancer J. 2015; 21(3):174-8. PMC: 4498162. DOI: 10.1097/PPO.0000000000000118. View

10.

de Visser K, Joyce J . The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell. 2023; 41(3):374-403. DOI: 10.1016/j.ccell.2023.02.016. View

11.

Wang G, Zhang M, Cheng M, Wang X, Li K, Chen J . Tumor microenvironment in head and neck squamous cell carcinoma: Functions and regulatory mechanisms. Cancer Lett. 2021; 507:55-69. DOI: 10.1016/j.canlet.2021.03.009. View

12.

Moaaz M, Lotfy H, Elsherbini B, Motawea M, Fadali G . TGF-β Enhances the Anti-inflammatory Effect of Tumor- Infiltrating CD33+11b+HLA-DR Myeloid-Derived Suppressor Cells in Gastric Cancer: A Possible Relation to MicroRNA-494. Asian Pac J Cancer Prev. 2020; 21(11):3393-3403. PMC: 8033108. DOI: 10.31557/APJCP.2020.21.11.3393. View

13.

Jia H, Qi H, Gong Z, Yang S, Ren J, Liu Y . The expression of FOXP3 and its role in human cancers. Biochim Biophys Acta Rev Cancer. 2019; 1871(1):170-178. DOI: 10.1016/j.bbcan.2018.12.004. View

14.

Tao L, Huang G, Song H, Chen Y, Chen L . Cancer associated fibroblasts: An essential role in the tumor microenvironment. Oncol Lett. 2017; 14(3):2611-2620. PMC: 5588104. DOI: 10.3892/ol.2017.6497. View

15.

Lui V, Hedberg M, Li H, Vangara B, Pendleton K, Zeng Y . Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov. 2013; 3(7):761-9. PMC: 3710532. DOI: 10.1158/2159-8290.CD-13-0103. View

16.

Umemura S, Mimaki S, Makinoshima H, Tada S, Ishii G, Ohmatsu H . Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis. J Thorac Oncol. 2014; 9(9):1324-31. PMC: 4154841. DOI: 10.1097/JTO.0000000000000250. View

17.

Lee J, Kang K, Lee H . Expression of phosphorylated mTOR and its clinical significances in small cell lung cancer. Int J Clin Exp Pathol. 2015; 8(3):2987-93. PMC: 4440117. View

18.

Cooper W, Lam D, OToole S, Minna J . Molecular biology of lung cancer. J Thorac Dis. 2013; 5 Suppl 5:S479-90. PMC: 3804875. DOI: 10.3978/j.issn.2072-1439.2013.08.03. View

19.

Riquelme I, Tapia O, Espinoza J, Leal P, Buchegger K, Sandoval A . The Gene Expression Status of the PI3K/AKT/mTOR Pathway in Gastric Cancer Tissues and Cell Lines. Pathol Oncol Res. 2016; 22(4):797-805. PMC: 5890336. DOI: 10.1007/s12253-016-0066-5. View

20.

De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S . KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 2010; 12(6):594-603. DOI: 10.1016/S1470-2045(10)70209-6. View